Algiax Pharmaceuticals

Aptinyx

This biopharmaceutical company develops small-molecule modulators of NMDA receptors to treat patients with chronic pain and central nervous system disorders.

Neurosterix

This biopharmaceutical company develops allosteric modulator therapeutics to treat patients suffering from neurological and neuropsychiatric disorders, including schizophrenia and mood disorders.

Allyx

This clinical-stage biotechnology company develops oral small molecule therapies to protect synapses in patients with Alzheimer's disease and other neurodegenerative conditions.

Axonis

This biotechnology company develops oral small molecule therapies targeting the KCC2 protein to treat patients with epilepsy, chronic pain and spinal cord injuries.

Axonis Therapeutics

This biotechnology firm develops small molecule therapies targeting the KCC2 protein to treat neurological conditions including epilepsy and pain for the healthcare industry.

Pangea Bio

This biotechnology company develops small molecule medicines for neurological and neuropsychiatric disorders using an artificial intelligence platform to identify compounds from natural sources.

Neurosciences

This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.

Latigo Biotherapeutics

This clinical-stage biopharmaceutical company develops non-opioid medicines to treat patients suffering from pain without the risk of addiction.